Use of isogenic human cancer cells for high-throughput screening and drug discovery.
about
Facile methods for generating human somatic cell gene knockouts using recombinant adeno-associated virusesA genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogeneFinding the needle in the haystack: why high-throughput screening is good for your health.Cancer of the Pancreas: Molecular Pathways and Current Advancement in TreatmentMechanisms of ferroptosisIn vitro human cell line models to predict clinical response to anticancer drugsMolecular therapy of colorectal cancer: progress and future directionsPreclinical mouse cancer models: a maze of opportunities and challenges.Oncogenomics and the development of new cancer therapiesA dual-color fluorescence-based platform to identify selective inhibitors of Akt signalingEvolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cellsThe power of chemical genomics to study the link between endomembrane system components and the gravitropic responseIdentification of cell surface and secreted proteins essential for tumor cell survival using a genetic suppressor element screen.shRNA libraries and their use in cancer genetics.Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model.Methodological approaches in application of synthetic lethality screening towards anticancer therapyRapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical modelsSynthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA deliveryInfrared spectroscopy characterization of normal and lung cancer cells originated from epithelium.Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.Targeting p53 for Novel Anticancer Therapy.Targeting the cancer kinome through polypharmacology.p300 regulates p53-dependent apoptosis after DNA damage in colorectal cancer cells by modulation of PUMA/p21 levels.Dual-fluorescence isogenic high-content screening for MUC16/CA125 selective agents.Antitumor activity of a novel oncrasin analogue is mediated by JNK activation and STAT3 inhibitionPowerful partners: Arabidopsis and chemical genomicsSynthetic lethality: general principles, utility and detection using genetic screens in human cellsmTORC2 is required for proliferation and survival of TSC2-null cells.Analyzing fission yeast multidrug resistance mechanisms to develop a genetically tractable model system for chemical biology.Development of synthetic lethality anticancer therapeutics.Anticancer drug mithramycin interacts with core histones: An additional mode of action of the DNA groove binder.Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation.The emergence of resistance to targeted cancer therapeutics.Analogues and derivatives of oncrasin-1, a novel inhibitor of the C-terminal domain of RNA polymerase II and their antitumor activities.Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stressIdentification of novel radiosensitizers in a high-throughput, cell-based screen for DSB repair inhibitors.MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms.A novel small molecule that selectively inhibits glioblastoma cells expressing EGFRvIII.
P2860
Q24633989-4F66F531-CECB-4D6A-A8E2-EB407D754E62Q24647664-9081B5A5-4673-4347-B12B-EFB99525E60DQ24802613-FD962AE7-8967-4AA0-B7DB-171203C11E0BQ26740619-315E9673-A733-4414-B12A-9F17ED88D1DFQ26751418-9A9A1A34-2601-422A-920A-9DA0E1629766Q27000665-43DFBE89-BA60-4FAA-9435-68FA02969C0AQ27005764-19A7B243-BBB5-4BAE-B93E-74AB2B8FDFA1Q27322080-8FD755D6-6E85-4891-9136-44CE33E476A0Q28263634-368E9E83-21C7-4E42-A1DB-8CEBB4DB0B45Q28472406-13277CEA-324F-4CA8-B12A-74A74A9C1E6FQ30531111-0B52F3EE-D8B1-4016-938D-0A2257063B0EQ30856823-93C6C0A5-45F8-47F2-BC5D-6FFDF3B81107Q31111319-BBBEBFF8-EFB5-4F0C-B2AF-E8062B25D77BQ33255055-6B8E080B-0E62-481A-8114-E98244FA0BFEQ33305157-9E52EF5B-12D3-44E8-A290-CCF5806352C1Q33316872-1E9D22B2-2999-42BD-A621-739D43932E72Q33421697-A0BC569C-494F-4094-8660-74979627DC0AQ33430534-51F3B902-6E45-4E14-901C-C0ED843A71E8Q33587012-16F02CBB-06C6-4B52-9141-665A429E6658Q33593730-5C3747C6-AC3C-4E9B-9351-D189DD12E09EQ33604028-46B0B5A4-4394-462D-A177-2977D7CB8EF7Q33655329-6883C819-73A1-4361-842D-C70144020FDEQ33893019-10F11385-B7E5-4E50-8317-D6D0E5911DE7Q33905382-13FD37C4-4636-43C2-A044-9002DDF75FADQ33982446-FC5031B9-1EDC-4971-AD7C-5F5D5CC4ED9DQ34103117-AD3EF220-0608-440E-9934-346091D79973Q34149856-0D72BC58-41B3-48B2-8FD0-56C34B6FFD79Q34151015-B701C448-3B90-4DC6-9617-B281F16BE290Q34177457-C8F38059-F583-47B3-9F4E-F614FED9EB18Q34290756-6F8D60E2-9AF4-4613-BE15-44DF74544231Q34380368-BE6E3E7E-FF27-4DB6-AF08-DFE828A953C3Q34585595-894A7AC2-EF3F-4AE6-9599-9F95081CC8ABQ34659415-AF8B2551-D893-428D-BBBD-52E87274B542Q34782417-A8888D3A-32CF-4E49-8DE1-4E688EFB0202Q34837015-1DB9F784-4FDA-49B5-A944-7D03B335D1BDQ34857289-638CBC8A-9898-430E-8A5A-AE39488C4475Q35008361-5003C355-88BE-45AE-A76D-D8D23FBB4DEFQ35523975-A957C4F8-A485-43C9-A948-063B053A6D92Q35677921-BFA76AB7-D8A7-4653-B4CA-04CE42B0ED67Q35757512-BC79546E-CB50-4CA6-BB5D-A7B74AA8A4B3
P2860
Use of isogenic human cancer cells for high-throughput screening and drug discovery.
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Use of isogenic human cancer cells for high-throughput screening and drug discovery.
@ast
Use of isogenic human cancer cells for high-throughput screening and drug discovery.
@en
Use of isogenic human cancer cells for high-throughput screening and drug discovery.
@nl
type
label
Use of isogenic human cancer cells for high-throughput screening and drug discovery.
@ast
Use of isogenic human cancer cells for high-throughput screening and drug discovery.
@en
Use of isogenic human cancer cells for high-throughput screening and drug discovery.
@nl
prefLabel
Use of isogenic human cancer cells for high-throughput screening and drug discovery.
@ast
Use of isogenic human cancer cells for high-throughput screening and drug discovery.
@en
Use of isogenic human cancer cells for high-throughput screening and drug discovery.
@nl
P2860
P356
P1433
P1476
Use of isogenic human cancer cells for high-throughput screening and drug discovery.
@en
P2093
Torrance CJ
P2860
P2888
P304
P356
10.1038/NBT1001-940
P577
2001-10-01T00:00:00Z
P5875
P6179
1019670801